2026 represents a critical inflection point for EU MDR compliance.
As highlighted in our recent webinar led by Arkan Zwick, PhD, manufacturers are moving beyond implementation into a phase of regulatory maturity, where expectations from notified bodies and authorities are higher, reviews are more detailed, and preparation is decisive.
This article summarizes the most relevant takeaways for manufacturers planning MDR transition, Annex XVI compliance, and notified body engagement in 2026.
1. Why 2026 Matters for MDR Manufacturers
Although MDR has applied since May 2021, many products remain on the EU market under extended transition timelines. In 2026, those extensions are approaching their limits.
Key drivers making 2026 a turning point include:
- Progression toward the end of MDR transition periods
- EUDAMED advancing toward operational use
- Increasingly consistent scrutiny across notified bodies
- Early discussions on potential MDR revisions
Together, these developments signal that transition relief will no longer compensate for weak preparation.
2. MDR Today: What "Higher Scrutiny" Means in Practice
MDR strengthened oversight across the entire device lifecycle. Manufacturers experience this most clearly during conformity assessment.
Under MDR, notified bodies focus more on:
- Depth and robustness of clinical evidence
- Consistency across technical documentation
- Post-market surveillance and clinical follow-up
- Clear accountability of all economic operators
- Transparency through EU databases
As a result, longer review timelines and more deficiency letters are now the norm—especially where documentation is incomplete or inconsistent.
3. Annex XVI: Full MDR Obligations for Non-Medical Purpose Devices
Products without a medical purpose listed in Annex XVI (such as dermal fillers and aesthetic devices) are now fully within the scope of MDR—with no simplification.
Annex XVI: What Changes for Manufacturers
| Topic | Key Impact |
| Regulatory scope | MDR applies in full |
| Common Specifications (CS) | Legally binding minimum requirements |
| Clinical expectations | Long-term safety and performance focus |
| Labeling & IFU | Additional, specific user and consumer requirements |
Meeting MDR alone is not sufficient; ignoring CS requirements leads directly to non-compliance.
4. Annex XVI Transition: Timelines and Conditions
Transition deadlines vary depending on certification status and clinical strategy.
| Manufacturer Profile | Transition End | Key Requirement |
| With clinical investigations | Dec 2029 | Early NB engagement and clinical timelines |
| Without clinical investigations | Dec 2028 | NB agreement by Jan 2027 |
| Legacy MDD-certified devices | 2027 / 2028 | Compliance with Regulation (EU) 2023/607 |
Transition applies only if conditions are met—it is not automatic.
5. MDR Transition Under Regulation (EU) 2023/607
Manufacturers relying on extended transition must demonstrate ongoing eligibility.
Core requirements include:
- Continuous compliance with MDD
- No significant changes to design or intended purpose
- MDR-compliant QMS in place
- MDR application submitted on time
- Written agreement with a notified body
Manufacturers should also maintain objective evidence (e.g. NB letters or Free Sale Certificates) to support market access and international registrations.
6. Technical Documentation: A Living System, Not a Static File
Under MDR, technical documentation is embedded in the quality management system and must evolve over the product lifecycle.
Core MDR Technical Documentation Elements
| Area | Purpose |
| Device description & intended use | Defines regulatory scope |
| Risk management & benefit-risk | Supports safety justification |
| Clinical & pre-clinical data | Demonstrates performance |
| PMS & PMCF | Confirms real-world safety |
| PSUR | Ongoing regulatory reporting |
Even in 2026, incomplete documentation remains one of the most common causes of review delays across notified bodies.
7. Regulatory Strategy: Engage Early, Not Late
A key webinar message was clear: regulatory success starts in development.
Effective MDR strategies include:
- Early definition of intended use and claims
- Continuous drafting of technical documentation
- Structured, proactive dialogue with notified bodies
- Early alignment on clinical and pre-clinical strategy
- Integration of PMS and PMCF planning before CE marking
This approach significantly reduces later-stage surprises and timeline risk.
8. Practical Priorities for Manufacturers in 2026
Manufacturers preparing for MDR in 2026 should focus on four areas:
1. Secure transition and compliance continuity
Strong governance and clear internal ownership are essential.
2. Prepare for EUDAMED go-live
Confirm SRNs, readiness for data registration, and vigilance processes.
3. Strengthen regulatory dialogue
Clinical considerations should lead—not follow—development decisions.
4. Invest in documentation excellence
Completeness and consistency directly influence review speed.
How Qualtech Supports MDR Success
Navigating MDR in 2026 requires more than regulatory knowledge—it requires structured execution.
Qualtech supports manufacturers by:
- Building and remediating MDR-compliant technical documentation
- Supporting Annex XVI and Common Specification compliance
- Managing notified body interactions and deficiency responses
- Strengthening PMS, PMCF, and lifecycle documentation strategies
- Supporting MDR transition planning and governance
With regulatory expectations continuing to rise, expert guidance helps turn compliance from a risk into a competitive advantage.
Final Thought
Prepared manufacturers will still succeed under MDR—but preparation must be deliberate.
Early planning, strong documentation, and proactive regulatory engagement are now the defining factors for EU market access in 2026 and beyond.